| dc.contributor.author |
Gaikwad, Anil Bhanudas |
|
| dc.date.accessioned |
2025-03-17T10:20:05Z |
|
| dc.date.available |
2025-03-17T10:20:05Z |
|
| dc.date.issued |
2024-03 |
|
| dc.identifier.uri |
https://www.tandfonline.com/doi/full/10.1080/08923973.2024.2330641 |
|
| dc.identifier.uri |
http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/18391 |
|
| dc.description.abstract |
Acute kidney injury (AKI) is a critical global health issue associated with high mortality rates, particularly in patients undergoing renal transplants and major surgeries. These individuals often receive immunosuppressants to dampen immune responses, but the impact of these drugs on AKI remains unclear. |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
Taylor & Francis |
en_US |
| dc.subject |
Pharmacy |
en_US |
| dc.subject |
Immune system |
en_US |
| dc.subject |
Immunosuppressant |
en_US |
| dc.subject |
Acute kidney injury (AKI) |
en_US |
| dc.subject |
Immune checkpoint inhibitors |
en_US |
| dc.subject |
Monoclonal antibodies |
en_US |
| dc.title |
Immunosuppressants against acute kidney injury: what to prefer or to avoid? |
en_US |
| dc.type |
Article |
en_US |